HK1079797A1 - Remodeling and glycoconjugation of peptides - Google Patents

Remodeling and glycoconjugation of peptides

Info

Publication number
HK1079797A1
HK1079797A1 HK05111922.5A HK05111922A HK1079797A1 HK 1079797 A1 HK1079797 A1 HK 1079797A1 HK 05111922 A HK05111922 A HK 05111922A HK 1079797 A1 HK1079797 A1 HK 1079797A1
Authority
HK
Hong Kong
Prior art keywords
glycoconjugation
remodeling
peptides
Prior art date
Application number
HK05111922.5A
Other languages
English (en)
Inventor
Frees Shawn De
David Zopf
Robert Bayer
Caryn Bowe
David Hakes
Xi Chen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of HK1079797A1 publication Critical patent/HK1079797A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2445—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
HK05111922.5A 2001-10-10 2005-12-23 Remodeling and glycoconjugation of peptides HK1079797A1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US32852301P 2001-10-10 2001-10-10
US34469201P 2001-10-19 2001-10-19
US33423301P 2001-11-28 2001-11-28
US33430101P 2001-11-28 2001-11-28
US38729202P 2002-06-07 2002-06-07
US39177702P 2002-06-25 2002-06-25
US39659402P 2002-07-17 2002-07-17
US40424902P 2002-08-16 2002-08-16
US40752702P 2002-08-28 2002-08-28
PCT/US2002/032263 WO2003031464A2 (en) 2001-10-10 2002-10-09 Remodeling and glycoconjugation of peptides

Publications (1)

Publication Number Publication Date
HK1079797A1 true HK1079797A1 (en) 2006-04-13

Family

ID=27578810

Family Applications (4)

Application Number Title Priority Date Filing Date
HK05111922.5A HK1079797A1 (en) 2001-10-10 2005-12-23 Remodeling and glycoconjugation of peptides
HK11107561.1A HK1149513A1 (en) 2001-10-10 2005-12-23 Remodelling and glycoconjugation of human growth hormone (hgh)
HK06100136.9A HK1080090B (zh) 2001-10-10 2006-01-04 肽的重構和糖綴合的方法
HK11108713.6A HK1154498A1 (en) 2001-10-10 2011-08-18 Remodelling and glycoconjugation of interferon-alpha(ifna)

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK11107561.1A HK1149513A1 (en) 2001-10-10 2005-12-23 Remodelling and glycoconjugation of human growth hormone (hgh)
HK06100136.9A HK1080090B (zh) 2001-10-10 2006-01-04 肽的重構和糖綴合的方法
HK11108713.6A HK1154498A1 (en) 2001-10-10 2011-08-18 Remodelling and glycoconjugation of interferon-alpha(ifna)

Country Status (20)

Country Link
US (3) US7416858B2 (ko)
EP (7) EP1578771B1 (ko)
JP (8) JP5232352B2 (ko)
CN (3) CN1635901B (ko)
AU (2) AU2002360264B2 (ko)
BE (1) BE2014C004I2 (ko)
BR (1) BRPI0213207B1 (ko)
CA (1) CA2462930C (ko)
DK (2) DK1578771T3 (ko)
ES (9) ES2561985T3 (ko)
FR (1) FR14C0007I2 (ko)
HK (4) HK1079797A1 (ko)
IL (3) IL161251A0 (ko)
LU (1) LU92359I2 (ko)
MX (1) MXPA04003333A (ko)
NL (1) NL300912I2 (ko)
NZ (1) NZ532027A (ko)
PT (2) PT2279755E (ko)
SG (2) SG177002A1 (ko)
WO (1) WO2003031464A2 (ko)

Families Citing this family (307)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20030171267A1 (en) 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7112410B1 (en) 2001-08-29 2006-09-26 Human Genome Sciences, Inc. Human tumor necrosis factor TR21 and methods based thereon
US7439043B2 (en) * 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
CA2756610C (en) * 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
EP1997829A1 (en) * 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
CA2494223C (en) * 2002-08-01 2012-10-02 National Research Council Of Canada Campylobacter glycans and glycopeptides
EP2322209A3 (en) 2002-08-20 2012-02-01 Glykos Finland Oy Tumor specific oligosaccharide epitopes and use thereof
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
CA2500653A1 (en) 2002-10-16 2004-04-29 The Scripps Research Institute Glycoprotein synthesis
JP4699028B2 (ja) * 2002-11-08 2011-06-08 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 血小板の生存を延長するための組成物および方法
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
CA2520970A1 (en) * 2003-04-09 2004-10-28 Robert G. Schaub Hemophilia treatment by inhalation of coagulation factors
EP2338333B1 (en) * 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
ATE540055T1 (de) * 2003-05-09 2012-01-15 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glykosylierungsmutanten des menschlichen wachstumshormons
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
DK2213295T3 (da) * 2003-10-24 2013-05-06 Nora Therapeutics Inc Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20070254834A1 (en) * 2003-11-24 2007-11-01 Defrees Shawn Glycopegylated Erythropoietin
EP1711513B1 (en) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration of factor vii solutions to remove virus
BRPI0417342A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator estimulante de colÈnia de granulócitos glicopeguilado
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
MXPA06006023A (es) * 2003-12-03 2006-08-23 Neose Technologies Inc Factor ix glicopegilado.
WO2005058283A2 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
US8361961B2 (en) * 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
NZ548308A (en) * 2004-01-26 2010-11-26 Biogenerix Ag Branched polymeric sugars and nucleotides thereof
AU2005208897B2 (en) * 2004-01-26 2011-05-19 Ratiopharm Gmbh Branched polymeric sugars and nucleotides thereof
KR20070007086A (ko) * 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
HUE027902T2 (en) * 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2005094898A2 (en) * 2004-03-23 2005-10-13 Amgen Inc. Chemically modified protein compositions and methods
US20080305518A1 (en) * 2004-05-04 2008-12-11 Novo Nordisk Healthcare A/G O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
US8052667B2 (en) 2004-09-07 2011-11-08 Velico Medical, Inc. Apparatus for prolonging survival of platelets
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
MX2007003907A (es) * 2004-10-05 2007-05-21 Genentech Inc Agentes terapeuticos con toxicidad reducida.
ES2363700T3 (es) * 2004-10-15 2011-08-12 Velico Medical, Inc. Composiciones y métodos para prolongar la supervivencia de plaquetas.
US20080064059A1 (en) 2004-10-20 2008-03-13 Scripps Research Institute In Vivo Site-Specific Incorporation of N-Acetyl-Galactosamine Amino Acids in Eubacteria
SI2586456T1 (sl) * 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
WO2006066258A2 (en) * 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
US9187549B2 (en) 2004-12-23 2015-11-17 Novo Nordisk Healthcare A/G Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
WO2006074279A1 (en) * 2005-01-06 2006-07-13 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
AU2006203792B2 (en) * 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
EP1844068A4 (en) * 2005-01-25 2009-09-30 Apollo Life Sciences Ltd MOLECULES AND THEIR CHIMERIC MOLECULES
CN101146823A (zh) * 2005-02-15 2008-03-19 阿波罗生命科学有限公司 分子及其嵌合分子
WO2006094810A2 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
ATE527371T1 (de) * 2005-03-24 2011-10-15 Biogenerix Ag Expression löslicher, aktiver, eukaryotischer glucosyltransferasen in prokaryotischen organismen
WO2006105426A2 (en) * 2005-03-30 2006-10-05 Neose Technologies, Inc. Manufacturing process for the production of peptides grown in insect cell lines
WO2006106997A1 (ja) 2005-03-31 2006-10-12 The Noguchi Institute 生体試料の解析法及び疾患マーカーの検索法
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
CA2609702C (en) 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Antibody conjugates via heterobifunctional peg linkers
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
JP2009515508A (ja) * 2005-08-19 2009-04-16 ネオス テクノロジーズ インコーポレイテッド グリコｐｅｇ化因子ｖｉｉおよび因子ｖｉｉａ
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1937306B1 (en) * 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
JP5894722B2 (ja) 2005-09-01 2016-03-30 ノボ ノルディスク ヘルス ケア アーゲー 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製
EP1926817A2 (en) 2005-09-14 2008-06-04 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
JP5552231B2 (ja) * 2005-10-14 2014-07-16 ベリコ メディカル インコーポレイティッド 血小板の生存延長のための組成物および方法
AU2006304856A1 (en) * 2005-10-21 2007-04-26 Synageva Biopharma Corp. Glycolated and glycosylated poultry derived therapeutic proteins
WO2007056191A2 (en) * 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
ES2677555T3 (es) * 2005-11-23 2018-08-03 Ventana Medical Systems, Inc. Conjugado molecular
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP3438131B1 (en) 2006-02-10 2022-03-16 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
JP2009534034A (ja) 2006-04-19 2009-09-24 ノヴォ ノルディスク アクティーゼルスカブ 原核微生物におけるｏ−グリコシル化治療用タンパク質の発現
EP2581450B1 (en) 2006-05-02 2018-08-15 MedImmune Limited Non-natural amino acid substituted polypeptides
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
WO2007146847A2 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
JP2009544327A (ja) * 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
CN101511391B (zh) 2006-07-25 2013-03-13 利普生技术有限公司 N末端聚唾液酸化
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2068907B1 (en) * 2006-10-04 2017-11-29 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
NO2457920T3 (ko) 2007-01-18 2018-03-24
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
DK2068909T3 (da) * 2007-03-30 2012-08-06 Ambrx Inc Modificerede FGF-21-polypeptider og anvendelse heraf
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
WO2008124706A2 (en) 2007-04-06 2008-10-16 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Devices and methods for target molecule characterization
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
WO2009012502A1 (en) * 2007-07-19 2009-01-22 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Self- anchoring mems intrafascicular neural electrode
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
CN104689333B (zh) 2007-08-27 2018-05-29 拉蒂奥法姆有限责任公司 G-csf 缀合物的液体制剂
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
AU2009204495B2 (en) * 2008-01-07 2013-10-24 Synageva Biopharma Corp. Glycosylation in avians
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
US8961757B2 (en) 2008-03-18 2015-02-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Nanopore and carbon nanotube based DNA sequencer
WO2009117522A2 (en) 2008-03-18 2009-09-24 Reinhart, Kevin Nanopore and carbon nanotube based dna sequencer and a serial recognition sequencer
EP2304046A4 (en) * 2008-06-25 2011-11-23 Bayer Healthcare Llc FACTOR VIII MUTES WITH REDUCED IMMUNOGENITY
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US8968540B2 (en) 2008-10-06 2015-03-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Trans-base tunnel reader for sequencing
BRPI0923047B8 (pt) 2008-12-16 2021-05-25 Genzyme Corp métodos para preparação de conjugados de proteínas- oligossacarídeos
MA33064B1 (fr) * 2009-01-28 2012-02-01 Smartcells Inc Systemes à base de conjugués pour administration contrôlée de médicaments
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20120035120A1 (en) 2009-03-25 2012-02-09 Seneb Biosciences, Inc. Glycolipids as treatment for disease
ES2427627T3 (es) 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
CA2768155C (en) * 2009-06-16 2016-08-23 The University Of Bath Materials and methods relating to glycosylation
NZ623810A (en) 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
CN102497884A (zh) * 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
BR112012008665A2 (pt) 2009-10-12 2016-11-22 Pfizer tratamento de câncer
US8697844B2 (en) 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EP2977055A1 (en) 2010-02-16 2016-01-27 Novo Nordisk A/S Factor viii fusion protein
ES2639398T3 (es) 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
CA2794740C (en) 2010-04-01 2019-12-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US8962345B2 (en) * 2010-05-21 2015-02-24 The United States Of America As Represented By The Secretary Of Commerce Method of characterizing glycans attached to glycoproteins
EP2588499B1 (en) 2010-06-30 2020-04-08 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
US9670475B2 (en) 2010-07-09 2017-06-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
CN102971006A (zh) 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
JP2013535198A (ja) 2010-07-30 2013-09-12 グリコド 哺乳類のグリコシル化経路を有する酵母人工染色体
EP2415779B1 (en) 2010-08-02 2015-01-21 ratiopharm GmbH Method of producing and purifying an active soluble sialyltransferase
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
JP2013542188A (ja) 2010-09-22 2013-11-21 ノヴォ ノルディスク アー／エス 治療用第ｖｉｉｉ因子抗体
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2651433A1 (en) 2010-12-16 2013-10-23 Novo Nordisk A/S Aqueous factor viii solution
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
BR112013016447A2 (pt) * 2011-01-06 2019-09-24 Univ Johns Hopkins método de produção de glicoproteínas recombinantes com meia-vida circulatória aumentada em células de mamífero
BR112013017980A2 (pt) 2011-01-14 2017-06-27 Redwood Bioscience Inc polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
JP2014518608A (ja) * 2011-02-25 2014-08-07 メルク・シャープ・アンド・ドーム・コーポレーション 修飾ｏ−グリコシル化を有するタンパク質の製造のための酵母株
US9737612B2 (en) 2011-03-01 2017-08-22 Novo Nordisk A/S Antagonistic DR3 ligands
CN103429256B (zh) 2011-03-02 2022-09-13 诺和诺德保健股份有限公司 凝血因子向活化的血小板上的tlt-1的靶向
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
JP2014509864A (ja) 2011-03-23 2014-04-24 グリコド Ｇｄｐ−フコースを産生可能な酵母組換え細胞
CA2830972C (en) 2011-04-19 2018-11-20 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CA2836574C (en) * 2011-05-18 2021-11-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
AU2012255116B2 (en) 2011-05-18 2017-05-25 Mederis Diabetes, Llc Improved peptide pharmaceuticals
US9765158B2 (en) 2011-05-31 2017-09-19 Probiogen Ag Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
ES2582869T3 (es) 2011-07-05 2016-09-15 Bioasis Technologies Inc Conjugados de P97-anticuerpo
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
IN2014CN02982A (ko) * 2011-10-01 2015-07-03 Glytech Inc
KR101456174B1 (ko) * 2011-10-18 2014-11-03 한국생명공학연구원 용해도가 증가된 비―퀴논 젤다나마이신 당전이 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이의 열충격 단백질(Ｈｓｐ90) 에이티피아제(ＡＴＰａｓｅ) 활성 저해용 약학적 조성물
WO2013058582A2 (ko) * 2011-10-18 2013-04-25 한국생명공학연구원 당전이 효소를 이용한 안사마이신 배당체의 제조방법
US9034829B1 (en) 2011-10-27 2015-05-19 Northwestern University pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
GB2503131B (en) 2012-02-21 2015-11-18 Cytonics Corp Systems, compositions and methods for transplantation
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
US20150045303A1 (en) 2012-04-24 2015-02-12 Novo Nordisk A/S Pharmaceutical Composition Suitable for Treatment of Haemophilia
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CN102786030B (zh) * 2012-07-06 2014-03-12 江苏大学 一种通过溶剂处理制备多肽纳米薄膜的方法
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
CN104662150B (zh) 2012-07-31 2018-07-10 比奥阿赛斯技术有限公司 脱磷酸化的溶酶体贮积症蛋白及其使用方法
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2885796C (en) 2012-09-24 2022-05-03 Allozyne, Inc. Cell lines
WO2014057069A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide
WO2014059144A1 (en) 2012-10-10 2014-04-17 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Systems and devices for molecule sensing and method of manufacturing thereof
JP2015532307A (ja) 2012-10-15 2015-11-09 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 凝固因子ｖｉｉポリペプチド
JP2015533152A (ja) 2012-10-15 2015-11-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 第ｖｉｉ因子コンジュゲート
BR112015011478B1 (pt) * 2012-11-20 2022-10-25 Mederis Diabetes, Llc Produtos de peptídeo, seus usos e composição farmacêutica
CA3157899A1 (en) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
CN103044509B (zh) * 2013-01-05 2015-04-01 宁辉 γ-胞嘧啶核苷-5’-三磷酸二钠结晶化合物、其制备方法及其药物组合物
SG10201809779RA (en) * 2013-03-11 2018-12-28 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
CN105209497B (zh) 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
EP2991683B1 (en) 2013-05-02 2019-09-18 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
JP2016520586A (ja) * 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015031654A2 (en) 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
AU2014317889B2 (en) 2013-09-06 2020-03-05 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
CN105792852B (zh) 2013-10-04 2019-12-10 默沙东公司 葡萄糖响应性的胰岛素缀合物
WO2015057064A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
EP3057618B1 (en) * 2013-10-14 2022-12-14 SynAffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
CN105637088A (zh) 2013-10-15 2016-06-01 诺和诺德保健股份有限公司 凝固因子vii多肽
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
EP3094352B1 (en) 2014-01-16 2020-09-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015112016A1 (en) 2014-01-24 2015-07-30 Synaffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
US20170009266A1 (en) * 2014-01-24 2017-01-12 Synaffix B.V. Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
CN106660967A (zh) 2014-01-24 2017-05-10 西纳福克斯股份有限公司 (杂)芳基1，3‑偶极化合物与(杂)环炔的环加成方法
CA2935195A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
EP3107562B1 (en) 2014-02-19 2019-09-18 Bioasis Technologies Inc. P97-ids fusion proteins
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
JP6750148B2 (ja) * 2014-04-25 2020-09-02 公益財団法人野口研究所 糖鎖切断抗体の製造方法及び均一糖鎖抗体
JP6847664B2 (ja) 2014-05-01 2021-03-24 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７−ポリヌクレオチド複合体
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3904388A1 (en) 2014-05-27 2021-11-03 Academia Sinica Fucosidase from bacteroides and methods using the same
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
BR112016027595B1 (pt) 2014-05-28 2023-12-26 Mederis Diabetes, Llc Produto de peptídeos, composição farmacêutica e seus usos
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10532097B2 (en) * 2014-07-10 2020-01-14 Academia Sinica Multi-drug delivery system and use thereof
CA2956412A1 (en) 2014-08-04 2016-02-11 Csl Limited Factor viii formulation
KR102422375B1 (ko) 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US10889631B2 (en) 2014-11-20 2021-01-12 Cytonics Corporation Therapeutic variant alpha-2-macroglobulin compositions
WO2016091268A2 (en) 2014-12-12 2016-06-16 University Of Copenhagen N-glycosylation
RS61470B1 (sr) 2014-12-31 2021-03-31 Checkmate Pharmaceuticals Inc Kombinovana antitumorska imunoterapija
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
US11155601B2 (en) 2015-03-06 2021-10-26 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
CA3008017C (en) * 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
IL259659B (en) 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
AU2017205268B2 (en) 2016-01-08 2022-02-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
PL3400019T3 (pl) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
MA45473A (fr) * 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
JP6852397B2 (ja) * 2016-12-28 2021-03-31 株式会社島津製作所 分析用試料の調製方法および分析方法
CN110121365A (zh) * 2016-12-29 2019-08-13 财团法人生物技术开发中心 制备糖蛋白-药物偶联物的方法
PE20191551A1 (es) 2017-02-17 2019-10-24 Denali Therapeutics Inc Polipeptidos de union al receptor de transferrina disenados
JP2020511499A (ja) 2017-03-20 2020-04-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
CA3069321A1 (en) 2017-07-11 2019-01-17 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
MX2020001332A (es) 2017-08-03 2020-09-09 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas.
CN114601932A (zh) 2017-09-04 2022-06-10 89生物有限公司 突变型fgf-21肽缀合物及其用途
BR112020010694A2 (pt) 2017-12-01 2020-11-10 Abbvie Inc. agonista de receptor de glicocorticoides e imunoconjugados do mesmo
CN111818971A (zh) 2018-01-03 2020-10-23 梅德瑞斯糖尿病有限责任公司 用于治疗nash和其他紊乱的改进的肽药物
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
EP3790574A4 (en) * 2018-05-30 2022-07-13 Purdue Research Foundation TARGETING ANABOLIC DRUGS TO ACCELERATE FRACTURE REPAIR
CN113301925A (zh) 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法
BR112021014415A2 (pt) 2019-02-06 2021-09-21 Synthorx, Inc. Conjugados de il-2 e métodos de uso dos mesmos
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
IL293994A (en) 2019-12-23 2022-08-01 Denali Therapeutics Inc Variants of progranulin, preparations containing them and their uses
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
WO2022029496A1 (en) * 2020-08-07 2022-02-10 Eutilex Co., Ltd. Anti-her2 / anti-4-1bb bispecific antibodies and uses thereof
JP2023554215A (ja) * 2020-10-16 2023-12-27 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド 糖共役体
US20230372528A1 (en) * 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022136705A1 (en) * 2020-12-24 2022-06-30 Synaffix B.V. Glycan-conjugated antibodies binding to fc-gamma receptor
CN113429443B (zh) * 2021-07-08 2023-07-25 江南大学 一种双唾液酸-甘露寡糖复合物及其合成方法
CA3241577A1 (en) * 2021-12-20 2023-06-29 Shaji Joseph Chemical synthesis of cytidine-5'-monophospho-n-glycyl-sialic acid
WO2024145600A1 (en) * 2022-12-29 2024-07-04 Honeybear Biosciences Inc. Method for glycoprotein modification

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (ko) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4385260A (en) * 1975-09-09 1983-05-24 Beckman Instruments, Inc. Bargraph display
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
IL63270A0 (en) 1980-08-05 1981-10-30 Univ Leland Stanford Junior Eukaryotic autonomously replicating segment
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4975276A (en) 1982-01-15 1990-12-04 Cetus Corporation Interferon-alpha 54
US4748233A (en) 1982-03-23 1988-05-31 Bristol-Myers Company Alpha-interferon Gx-1
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0096910B1 (en) 1982-05-19 1989-04-19 Unilever N.V. Yeast of the genus kluyveromyces modified for the expression of preprothaumatin or its various allelic and modified forms or their maturation forms
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US5151511A (en) 1982-09-16 1992-09-29 Amgen Inc. DNA encoding avian growth hormones
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DK168016B1 (da) 1983-12-26 1994-01-17 Kyowa Hakko Kogyo Kk Derivat af humant interferon-gamma-polypeptid
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
WO1986006408A1 (en) 1985-04-22 1986-11-06 Genetics Institute, Inc. HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
US4735040A (en) 1985-04-30 1988-04-05 Buro Patent Ag Method of and apparatus for the automatic feeding of filled cans and the automatic removal of empty cans from the spinning units of a spinning machine
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS6238172A (ja) 1985-08-12 1987-02-19 株式会社　高研 抗血栓性医用材料の製造方法
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62236497A (ja) 1985-09-17 1987-10-16 Chugai Pharmaceut Co Ltd 顆粒球コロニー刺激因子活性を有する糖蛋白質の製造方法
EP0238655A4 (en) 1985-10-03 1989-09-11 Biogen Nv POLYPEPTIDES LIKE THE GRANULOCYTE-MACROPHOUS COLONY STIMULATION FACTORS (GM-CSF) AND THEIR METHODS OF PRODUCING LARGE QUANTITIES IN MICROBIAL CELLS.
IL80529A0 (en) 1985-11-14 1987-02-27 Daiichi Seiyaku Co Method of producing peptides
DE3712985A1 (de) 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
JPS63502716A (ja) * 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
IT1203758B (it) 1986-03-27 1989-02-23 Univ Roma Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4894330A (en) 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
DK175243B1 (da) 1987-03-23 2004-07-19 Zymogenetics Inc Ekspressionsvektor, der er i stand til at styre ekspression af heterologe gener eller cDNA i gær, gærværtscelle samt fremgangsmåde til öget produktion af proteiner i gærværtsceller
IL82834A (en) 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
IL87258A (en) 1987-07-28 1994-02-27 Gist Brocades Nv SECYMOREVYULK surrogate cells and their use for the expression of polypeptides
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5252726A (en) 1987-09-04 1993-10-12 Novo Nordisk A/S Promoters for use in aspergillus
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8810808D0 (en) 1988-05-06 1988-06-08 Wellcome Found Vectors
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
FR2631974B1 (fr) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
FR2638643B1 (fr) 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
ATE176924T1 (de) 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5475090A (en) 1989-02-21 1995-12-12 Boyce Thompson Institute For Plant Research Gene coded for a polypeptide which enhances virus infection of host insects
US5194376A (en) 1989-02-28 1993-03-16 University Of Ottawa Baculovirus expression system capable of producing foreign gene proteins at high levels
DE3906540A1 (de) 1989-03-02 1990-09-13 Behringwerke Ag Expressionsvektoren zur synthese von proteinen in der spalthefe schizosaccharomyces pombe
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
CA2053317C (en) 1989-04-19 1996-03-12 Shmuel Zalipsky Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2038579T3 (es) 1989-04-28 1997-02-16 Rhein Biotech Proz & Prod Gmbh Celulas de levadura del genero schwanniomyces.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5179007A (en) 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5032519A (en) 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
DE4009630C2 (de) * 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
JP2975632B2 (ja) * 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
US5606031A (en) 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
US5492821A (en) * 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
US5420027A (en) 1991-01-10 1995-05-30 Board Of Regents, The University Of Texas System Methods and compositions for the expression of biologically active fusion proteins comprising a eukaryotic cytochrome P450 fused to a reductase in bacteria
US6288304B1 (en) 1991-02-22 2001-09-11 Sembiosys Genetics Inc. Expression of somatotropin in plant seeds
US5948682A (en) 1991-02-22 1999-09-07 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
US5650554A (en) 1991-02-22 1997-07-22 Sembiosys Genetics Inc. Oil-body proteins as carriers of high-value peptides in plants
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
CA2106301C (en) 1991-03-18 1999-04-06 Chi-Huey Wong Oligosaccharide enzyme substrates and inhibitors: method and compositions
US5212075A (en) 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5472858A (en) 1991-06-04 1995-12-05 Wisconsin Alumni Research Foundation Production of recombinant proteins in insect larvae
US5374655A (en) 1991-06-10 1994-12-20 Alberta Research Council Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
KR950014915B1 (ko) 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US5352570A (en) 1991-06-28 1994-10-04 Eastman Kodak Company Method and photographic material and process comprising a benzotriazole compound
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5633146A (en) 1991-07-02 1997-05-27 Rhone-Poulenc Rorer S.A. Method for producing recombinant proteins and host cells used therein
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
DK8892D0 (da) 1992-01-23 1992-01-23 Symbicom Ab Humant proteingen
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US5965106A (en) 1992-03-04 1999-10-12 Perimmune Holdings, Inc. In vivo binding pair pretargeting
AU678154B2 (en) 1992-04-02 1997-05-22 Sembiosys Genetics Inc. Oil-body protein cis-elements as regulatory signals
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
CA2141673A1 (en) * 1992-08-07 1994-02-17 Graham P. Allaway Non-peptidyl moiety-conjugated cd4-gamma2 and cd4-igg2 immunoconjugates, and uses thereof
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5348886A (en) 1992-09-04 1994-09-20 Monsanto Company Method of producing recombinant eukaryotic viruses in bacteria
KR950704497A (ko) 1992-11-27 1995-11-20 베르너 발데크 글리코실트랜스퍼라제 활성을 가진 단백질(Proteins Having Glycosyltransferase Activity)
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5202413A (en) 1993-02-16 1993-04-13 E. I. Du Pont De Nemours And Company Alternating (ABA)N polylactide block copolymers
US5374541A (en) 1993-05-04 1994-12-20 The Scripps Research Institute Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
AU691510B2 (en) * 1993-07-15 1998-05-21 Neose Pharmaceuticals Method of synthesizing saccharide compositions
DE4325317C2 (de) * 1993-07-29 1998-05-20 Univ Dresden Tech Verfahren zur radioaktiven Markierung von Immunglobulinen
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2179394A1 (en) 1993-12-23 1995-06-29 Kostas Iatrou Methods of expressing proteins in insect cells and methods of killing insects
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
US5369017A (en) * 1994-02-04 1994-11-29 The Scripps Research Institute Process for solid phase glycopeptide synthesis
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JP3090586B2 (ja) 1994-03-15 2000-09-25 片倉工業株式会社 システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5432059A (en) 1994-04-01 1995-07-11 Specialty Laboratories, Inc. Assay for glycosylation deficiency disorders
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
DE69526395D1 (de) 1994-08-13 2002-05-23 Roche Diagnostics Gmbh Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6010871A (en) * 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
US5521299A (en) 1994-11-22 1996-05-28 National Science Council Oligonucleotides for detection of baculovirus infection
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6287557B1 (en) 1995-02-21 2001-09-11 Cantab Pharmaceuticals Research Limited Methods of gene therapy using herpes viral vectors expressing GM-CSF
GB9506249D0 (en) 1995-03-27 1995-05-17 Karobio Ab Media for insect cell cultures
US5876980A (en) 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US6030815A (en) * 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US5922577A (en) 1995-04-11 1999-07-13 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5728554A (en) 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
EP0833663A4 (en) * 1995-05-15 1999-04-07 Constantin A Bona CARBOHYDRATE MEDIATED COUPLING OF PEPTIDES TO IMMUNOGLOBULINES
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU6255096A (en) 1995-06-07 1996-12-30 Mount Sinai School Of Medicine Of The City University Of New York, The Pegylated modified proteins
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5811634A (en) 1995-09-12 1998-09-22 Thomas G. O'Brien Transgenic mammal encoding ornithine decarboxylase
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5767379A (en) 1995-11-06 1998-06-16 John Howard Commercial production of avidin in plants
WO1997017451A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US5716812A (en) * 1995-12-12 1998-02-10 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides, and the products formed thereby
US5728580A (en) 1996-02-20 1998-03-17 Cornell Research Foundation, Inc. Methods and culture media for inducing single cell suspension in insect cell lines
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5734024A (en) 1996-04-19 1998-03-31 Boris Y. Zaslavsky Method for determining the biological activity of recombinant human growth hormone
US5750383A (en) 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system
WO1998002565A1 (en) 1996-07-17 1998-01-22 Zymogenetics, Inc. TRANSFORMATION OF $i(PICHIA METHANOLICA)
WO1998002536A2 (en) 1996-07-17 1998-01-22 Zymogenetics, Inc. Preparation of pichia methanolica auxotrophic mutants
US5682823A (en) 1996-08-23 1997-11-04 Bethlehem Steel Corporation Removable insulated cover and method for transporting hot oversized steel ingots
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
CA2268168C (en) 1996-10-10 2008-04-29 Cytel Corporation Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
US5856452A (en) 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
BR9606270A (pt) 1996-12-18 1998-09-22 Univ Minas Gerais Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
US5945314A (en) 1997-03-31 1999-08-31 Abbott Laboratories Process for synthesizing oligosaccharides
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
ATE285415T1 (de) 1997-06-13 2005-01-15 Gryphon Therapeutics Inc Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6210736B1 (en) 1997-06-17 2001-04-03 Genzyme Transgenics Corporation Transgenically produced prolactin
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
GB9722604D0 (en) * 1997-10-28 1997-12-24 Cancer Res Campaign Tech Heparin-binding growth factor derivatives
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6168937B1 (en) 1997-12-08 2001-01-02 Alan D. Elbein Purified β1,2-xylosyltransferase and uses thereof
US7244601B2 (en) 1997-12-15 2007-07-17 National Research Council Of Canada Fusion proteins for use in enzymatic synthesis of oligosaccharides
DE69913316T2 (de) 1998-01-07 2004-11-18 Debio Recherche Pharmaceutique S.A. Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
AR014491A1 (es) 1998-01-29 2001-02-28 Dow Agrosciences Llc Metodo para obtener plantas transgenicas fertiles de gossypium hirsutum.
ATE399809T1 (de) 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von polymerkonjugaten
US6689604B1 (en) 1998-03-20 2004-02-10 National Research Council Of Canada Lipopolysaccharide α-2,3 sialyltransferase of Campylobacter jejuni and its uses
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE69922978T2 (de) 1998-10-06 2005-12-08 Emalfarb, Mark Aaron, Jupiter Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
US6245539B1 (en) 1998-10-06 2001-06-12 Board Of Trustees Operating Michigan State University Human asparaginyl-tRNA synthetase DNA
DE69930015T2 (de) * 1998-10-16 2006-10-12 Biogen Idec Ma Inc., Cambridge Polymerkonjugate von interferon-beta-1a und deren verwendungen
US6374295B2 (en) * 1998-10-29 2002-04-16 Nortel Networks Limited Active server management
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
AU773845B2 (en) * 1998-11-18 2004-06-10 Neose Technologies, Inc. Low cost manufacture of oligosaccharides
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
DK1157037T3 (da) * 1999-01-29 2003-11-24 Hoffmann La Roche GCSF-konjugater
US6365410B1 (en) 1999-05-19 2002-04-02 Genencor International, Inc. Directed evolution of microorganisms
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
AU6357900A (en) * 1999-07-20 2001-02-05 Amgen, Inc. Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
EP1259563B2 (en) 1999-12-22 2016-08-10 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
HUP0203751A3 (en) * 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
US6423488B1 (en) 2000-01-15 2002-07-23 Avigenics, Inc High throughput screening assay for detecting a DNA sequence
AU2001232337A1 (en) 2000-02-18 2001-08-27 Kanagawa Academy Of Science And Technology Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
EP1299535A2 (en) 2000-06-30 2003-04-09 Maxygen Aps Peptide extended glycosylated polypeptides
WO2002004512A2 (en) 2000-07-10 2002-01-17 Diosynth Rtp, Inc. Purification of human troponin i
WO2002013873A2 (en) 2000-08-17 2002-02-21 Synapse Technologies, Inc. P97-active agent conjugates and their methods of use
AU2001283740A1 (en) 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
JP3894776B2 (ja) 2001-11-09 2007-03-22 富士通メディアデバイス株式会社 吐出装置および吐出方法
KR101186140B1 (ko) * 2002-06-21 2012-09-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페길화된 인자 ｖｉｉ 글리코형태
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
JP4251399B2 (ja) * 2004-05-21 2009-04-08 独立行政法人産業技術総合研究所 Ｏ結合型糖鎖が付加されたペプチドのスクリーニング方法

Also Published As

Publication number Publication date
JP2011006479A (ja) 2011-01-13
JP2010120954A (ja) 2010-06-03
WO2003031464A3 (en) 2006-03-02
FR14C0007I1 (fr) 2014-02-28
JP5739632B2 (ja) 2015-06-24
HK1149513A1 (en) 2011-10-07
IL161251A (en) 2013-07-31
EP2279755B1 (en) 2014-02-26
JP2009108087A (ja) 2009-05-21
JP2016037503A (ja) 2016-03-22
ES2619371T3 (es) 2017-06-26
JP2005521635A (ja) 2005-07-21
ES2538342T3 (es) 2015-06-19
NL300912I2 (nl) 2018-09-27
IL210257A (en) 2015-07-30
JP6316784B2 (ja) 2018-04-25
US7416858B2 (en) 2008-08-26
EP1578771B1 (en) 2013-03-06
ES2561985T3 (es) 2016-03-01
BR0213207A (pt) 2006-10-31
IL161251A0 (en) 2004-09-27
US7138371B2 (en) 2006-11-21
CN102180944A (zh) 2011-09-14
CN1635901A (zh) 2005-07-06
HK1080090A1 (en) 2006-04-21
EP2042196A2 (en) 2009-04-01
MXPA04003333A (es) 2006-02-22
PT2279755E (pt) 2014-06-04
EP2292271A2 (en) 2011-03-09
EP2279754B1 (en) 2014-08-13
DK2322229T3 (en) 2017-03-27
EP1578771A4 (en) 2007-02-21
SG159381A1 (en) 2010-03-30
US20060287223A1 (en) 2006-12-21
JP2016178938A (ja) 2016-10-13
DK1578771T3 (da) 2013-06-10
EP2279753A2 (en) 2011-02-02
EP2279754A2 (en) 2011-02-02
CN101724075B (zh) 2014-04-30
EP1578771A2 (en) 2005-09-28
JP2012143250A (ja) 2012-08-02
HK1154498A1 (en) 2012-04-27
HK1080090B (zh) 2012-12-14
US20040137557A1 (en) 2004-07-15
JP5232352B2 (ja) 2013-07-10
EP2292271A3 (en) 2011-09-14
JP2014087370A (ja) 2014-05-15
WO2003031464A2 (en) 2003-04-17
JP5258809B2 (ja) 2013-08-07
EP2042196A3 (en) 2009-07-22
EP2279755A2 (en) 2011-02-02
JP5376912B2 (ja) 2013-12-25
ES2606840T3 (es) 2017-03-28
AU2009202405B2 (en) 2011-09-22
EP2279753A3 (en) 2011-10-12
CN101724075A (zh) 2010-06-09
EP2080525B1 (en) 2015-12-16
CA2462930A1 (en) 2003-04-17
EP2279754A3 (en) 2011-06-22
LU92359I2 (fr) 2014-03-24
AU2002360264B2 (en) 2009-03-19
ES2516041T3 (es) 2014-10-30
FR14C0007I2 (fr) 2015-01-02
ES2411007T3 (es) 2013-07-04
CN1635901B (zh) 2012-03-28
EP2279755A3 (en) 2011-06-15
EP2080525A1 (en) 2009-07-22
EP2042196B1 (en) 2016-07-13
ES2556338T3 (es) 2016-01-15
US20050106658A1 (en) 2005-05-19
EP2279753B1 (en) 2015-09-16
ES2466024T3 (es) 2014-06-09
SG177002A1 (en) 2012-01-30
BE2014C004I2 (ko) 2021-11-22
BRPI0213207B1 (pt) 2021-06-15
PT2279753E (pt) 2016-01-15
CA2462930C (en) 2012-07-10
US7276475B2 (en) 2007-10-02
JP6321724B2 (ja) 2018-05-09
NZ532027A (en) 2008-09-26
ES2564688T3 (es) 2016-03-28
IL210257A0 (en) 2011-03-31
AU2009202405A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
IL210257A0 (en) Remodeling and glycoconjugation of peptides
EP1365022A4 (en) ADIPONECTIN-ASSOCIATED PROTEIN
GB0130557D0 (en) Proteins
GB0108079D0 (en) Protein
EP1414848A4 (en) REPLICINE PEPTIDES AND ITS USES
EP1419175A4 (en) PEPTIDES OF REPLIKIN AND THEIR USE
GB0130720D0 (en) Proteins
ZA200700168B (en) Remodeling and glycoconjugation of peptides
GB0100196D0 (en) Peptides
GB0109438D0 (en) Peptides
EP1360964A4 (en) USE OF A GALANINE-LIKE PEPTID
GB0108752D0 (en) Peptide epitopes and uses thereof
EP1395276A4 (en) STRUCTURALLY MODIFIED PEPTIDES AND THEIR USE
GB0103517D0 (en) Polypeptide
EP1373306A4 (en) PROTEINS ASSOCIATED WITH CYTOSKELETON
SG10201403662QA (en) Replikin peptides and uses thereof
GB0130560D0 (en) Proteins
GB0117737D0 (en) Modified peptides
GB0125372D0 (en) Modified peptides
IL159495A0 (en) Replikin peptides and uses thereof
IL158109A0 (en) Replikin peptides and uses thereof
GB0106318D0 (en) Protein
GB0126787D0 (en) Proteins
GB0111303D0 (en) Proteins
GB0130742D0 (en) Proteins

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221008